Grapiprant

Grapiprant is a non-steroidal anti-inflammatory drug (NSAID) used in veterinary medicine, primarily for the treatment of osteoarthritis pain and inflammation in dogs. It belongs to a class of drugs known as piprants, which selectively inhibit the prostaglandin E2 receptor 1 (EP4). This mechanism of action is distinct from other NSAIDs that typically target cyclooxygenase (COX) enzymes. By blocking the EP4 receptor, grapiprant reduces the inflammatory and pain signals associated with osteoarthritis.

The drug was developed by Elanco Animal Health and is marketed under the brand name Galliprant. It is administered orally, usually once daily. Clinical studies have shown grapiprant to be effective in improving the quality of life for dogs suffering from osteoarthritis, with observed improvements in mobility and a reduction in lameness. Common side effects can include gastrointestinal signs such as vomiting, diarrhea, and decreased appetite. However, compared to some traditional NSAIDs, grapiprant is considered to have a potentially better safety profile in dogs, particularly concerning gastrointestinal and renal toxicity, due to its targeted mechanism of action.

Veterinary professionals typically recommend grapiprant as part of a multimodal approach to managing osteoarthritis, which may also include weight management, physical therapy, and joint supplements. Its selective targeting of the EP4 receptor aims to minimize the potential for adverse effects often associated with broader COX inhibition. Before prescribing grapiprant, veterinarians will assess the individual dog's health status and history to ensure it is an appropriate treatment option.